Searched for
GENZYME
Aurobindo Pharma arm gets USFDA nod for Sevelamer hydrochloride tabletsAurobindo Pharma Ltd on Wednesday said its wholly-owned subsidiary APL Healthcare has received a final approval from the US health regulato...- Glenmark Pharma gets USFDA nod for drug for patients on dialysisThe approved product is a generic version of Genzyme Corporation's Renagel tablets.
- Cipla gets USFDA nod for generic version of Renvela tabletsThe approved product is a generic equivalent to the reference listed drug (RLD), Renvela tablets, 800 mg of Genzyme Corporation, said Cipla.
- IGST a bitter pill for patients with rare disorders as medicines attract 5%-12%While life-saving medicines imported for personal use would continue to be exempt from basic customs duty, they are not exempt from IGST.
- Dr Reddy's plunges nearly 2% on patent infringement suitDr Reddy's Laboratories plunged as much as 1.85% in a weak market on Monday after Genzyme Corporation filed a suit against the company.
- Genzyme Corporation files patent infringement suit against DRLMozobil (plerixafor injection) is a hematopoietic stem cell mobiliser indicated to patients with non-Hodgkin's lymphoma (blood cancer) and ...
- Genzyme signs deal with SIAMG to train doctors in geneticsGenzyme, announced a tie-up with the Society for Indian Academy of Medical Genetics, for a joint fellowship program for Indian doctors.
- Glenmark settles patent row with Daiichi, GenzymeGlenmark Pharmaceuticals on Monday said it has settled a patent infringement litigation with Daiichi Sankyo and Genzyme.
- Glenmark settles patent infringement litigation with Daiichi, GenzymeThe company has received a licence from Daiichi Sankyo and Genzyme that will permit it to launch its generic Colesevelam Hydrochloride prod...
- Glenmark settles litigation with Daiichi Sankyo; stock upGlenmark Pharmaceuticals has reached at a settlement agreement with Daiichi Sankyo, Inc and Genzyme Corporation in regards with Glenmark’s ...
- Sanofi extends $18.5 bn bid for Genzyme againIn a statement Sanofi-aventis said its offer of $69 per Genzyme share was extended till February 15 midnight.
- Sanofi extends $18.5bn offer for Genzyme till Jan 21Sanofi-aventis has a significant presence in India. Last year, Sanofi-aventis had sought to acquire an 80pc stake in ShanthaBiotechnics for...
- Sanofi extends bid for GenzymeFrench pharmaceutical giant Sanofi-Aventis said Monday it had extended its bid for US biotechnology group Genzyme without improving the off...
- Genzyme board rejects Sanofi $69-a-share offerBiotech firm Genzyme Corp. says its board of directors is rejecting Sanofi-Aventis SA's $69 a share offer and recommending Genzyme sharehol...
- Genzyme plans to cut 1000 jobs over next 15 monthsCambridge-based biotechnology company Genzyme, which rejected a $ 18.5 bn takeover offer from French pharma giant Sanofi Aventis, plans to ...
- Sanofi-Aventis likely to buy Genzyme for USD 19 bn: ReportFrench drug maker Sanofi-Aventis is likely to make an formal offer to acquire US-based biotech company Genzyme for USD 19 billion, says a m...
- Mitra Biotech gets VC fundingThe Bangalore-based Mitra Biotech, a biology research firm and spin-off from MIT, US, has received venture capital funding from Accel Partn...
- ‘Innovation can only be funded by branded therapies’In an e-mail interview with ET, Henri A Termeer, Chairman, President & CEO of Genzyme Corporation discusses the latest trends in the area o...
- Genzyme to set up R&D centres in IndiaThe company also plans to bring its complete range of global pipeline used to treat ultra rare diseases and set up research and manufacturi...
- Tata co ties up with Genzyme, Medicines for Malaria VentureAdvinus Therapeutics, a Bangalore-based research pharma company promoted by the Tata group, has announced a new collaboration with Genzyme ...
Load More
